Antitrust Antitrust

Bausch, Assertio see Humana’s pay-for-delay complaint partially dismissed by US judge

By Michael Acton
  • 05 Dec 2020 18:50
  • 05 Dec 2020 19:56
Bausch Health, Assertio Therapeutics and Lupin have convinced a US federal judge to partially dismiss an antitrust complaint from health insurance company Humana, which accused the companies of colluding to delay the market entry of generic versions of diabetes drug Glumetza.
In an order today, Judge William Alsup concluded Humana

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Michael Acton

Senior Correspondent

Michael is a senior correspondent for MLex in San Francisco, where he moved in 2020 after working in our Brussels bureau. Before joining MLex, he reported on EU politics as the Financial Times’ Nico Colchester Fellow in Brussels. Michael has a degree in International Relations and Politics from the University of Cambridge, and a degree in History and French from University College London and Paris IV Sorbonne.

Discover MLex

Stay on top of global regulatory developments

Latest News